Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Down 5.80%
As of Thursday, November 12, Arcturus Therapeutics Holdings Inc.’s ARCT share price has dipped by 5.80%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. ARCT
$8.48
-0.83
-8.92%
November 12, 2026 3:30:58 PM
EST
Volume: 265,284
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Commentary & Analysis
Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Up 11.81%
As of Friday, November 06, Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 11.81%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Down 11.27%
As of Thursday, November 05, Arcturus Therapeutics Holdings Inc.’s ARCT share price has dipped by 11.27%, which has investors questioning if this is right time to buy.Tudor Pop
What You Need to Know About Arcturus Therapeutics Holdings Inc.'s Q4 Earnings
Arcturus Therapeutics Holdings Inc.'s fiscal Q4 earnings report was released on Thursday, November 05. Let's dive in to see if (ARCT) missed or beat analyst's expectations.Rosalio Madrigal
Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Up 8.75%
As of Wednesday, November 04, Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 8.75%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $268.3 | $224.9 | 31% |
|
| Shares Out (Mil) | 28.4 | 54.9 | 36% |
|
| Institutional Ownership | 90.3% | 92.8% | 58% |
|
| Float (Mil) | 26.6 | 42.5 | 33% |
|
| Beta | 2.61 | 0.97 | 96% |
|
| Avg Daily Volume (000s) | 795 | 529 | 64% |
|
| Price Change (52-week) |
6.2% | 45.5% | 54% |
|
| Growth | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 53.9% | 13.6% | 96% |
|
| Net Income (5yr) | 1.8% | (10.3%) | 42% |
|
| EPS (5yr) | 7.5% | 15.8% | 43 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.2%) | (15.7%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 5 | 10 | |
| Current EPS | ($0.852) | ($2.904) | ($3.449) | |
| Month Ago EPS | ($0.929) | ($3.455) | ($3.703) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.903) | ($3.289) | ($3.718) | |
| Year/Year Chg | 226.4% | 20.9% | 47.8% | |
| Financials | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $31 | $41 | 16% |
|
| Net Income (TTM) (Mil) | ($87) | ($43) | 12% |
|
| EPS (TTM) | ($3.077) | ($1.500) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($63) | ($35) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($50) | $-0 | 21% |
|
| Long-Term Debt (Q1) (Mil) | $18 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $135 | $160 | 23% |
|
| Valuation | ARCT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.57 | 2.09 | 45% |
|
| P/E | na | 17.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (163.9%) | 67.8% | 1% |
|
| Net Margin | (285.9%) | (53.7%) | 3% |
|
| ROA | (35.1%) | (47.4%) | 15% |
|
| ROE | (44.4%) | (51.9%) | 16% |
|
| Liabilities to Assets | 21.6% | 29.6% | 14% |
|
| F-Score | 1 | 3 | 1% |
|
Passing Stock Screens
As of 11/11/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.3% |
| +/- S&P 500: | +13.9 |
FACTOR STRATEGY
Est Rev: Up 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 22.2% |
| +/- S&P 500: | +14.8 |
